


Novartis at ESMO

Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)

Sep 17, 2020

Novartis 2020 ESMO Annual Meeting Virtual Portal



We are boldly reimagining cancer and blood disorders.

[Enter Portal](#)

Press releases

- [Novartis announces new survival data for its treatment for advanced breast cancer with a specific mutation will be presented at the ESMO Virtual Congress 2020](#)
- [Novartis reports late-breaking data from Phase III study in advanced melanoma](#)
- [Novartis announces its advanced breast cancer treatment receives highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale](#)

Source URL: <https://prod1.novartis.com/news/novartis-esmo>

List of links present in page

1. <https://prod1.novartis.com/news/novartis-esmo>
2. https://www.virtualcongress.novartis.com/esmo20/?utm_medium=referral&utm_source=novartis.com&utm_campaign=corporate_website_post_oncology

3. <https://prod1.novartis.com/news/media-releases/novartis-kisqali-demonstrates-nearly-five-years-median-overall-survival-metastatic-breast-cancer>
4. <https://prod1.novartis.com/news/media-releases/novartis-reports-late-breaking-data-from-phase-iii-combi-i-trial-spartalizumab-pdr001-tafinlar-and-mekinist-advanced-melanoma>
5. <https://prod1.novartis.com/news/media-releases/novartis-kisqali-receives-highest-rating-any-cdk46-inhibitor-esmo-magnitude-clinical-benefit-scale>